Hillstream Biopharma (NASDAQ:CNTN) Shares Down 8% – What’s Next?

Hillstream Biopharma Inc. (NASDAQ:CNTN) fell 8% on Thursday. The stock traded as low as $2.05 and last traded at $2.08. 1,345,264 shares changed hands during mid-day trading, an increase of 51% from the average daily volume of 892,646 shares. The stock had previously closed at $2.26.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wall Street Zen raised Hillstream Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded Hillstream Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 28th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hillstream Biopharma Stock Performance

The company has a market cap of $168.13 million, a PE ratio of -4.22 and a beta of 1.46. The business’s 50-day moving average is $2.18 and its 200 day moving average is $2.68.

Hillstream Biopharma Company Profile

Hillstream Biopharma, Inc is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company’s research centers on ferroptosis, a form of regulated cell death that may offer a way to selectively target tumor cells, including cancer cells that have developed resistance to existing therapies.

Hillstream’s pipeline has included HSB-1216, an investigational ferroptosis-inducing therapy being evaluated for potential use in solid tumors. The company has also pursued additional preclinical oncology programs designed to address treatment-resistant cancers.